Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) is a rare platelet disorder caused by mutations in RUNX1. We generated an iPSC line (GENYOi005-A) from a FPDMM patient with a non-previously reported variant p.Thr196Ala. Non-integrative Sendai viruses expressing the Yamanaka reprogramming factors were used to reprogram peripheral blood mononuclear cells from this FPDMM patient. Characterization of GENYOi005-A included genetic analysis of RUNX1 locus, Short Tandem Repeats profiling, alkaline phosphatase enzymatic activity, expression of pluripotency-associated factors and differentiation studies in vitro and in vivo. This iPSC line will provide a powerful tool to study developmental alterations of FPDMM patients.
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Resource utility
GENYOi005-A is an iPSC line generated from a Familial platelet disorder with associated myeloid malignancy (FPDMM) patient with this new variant p.Thr196Ala in RUNX1. This cell line will be a very useful tool to understand hematopoiesis development and leukemogenesis of this RUNX1 variant.
Resource details
Familial platelet disorder with associated myeloid malignancy (FPDMM) is an autosomal dominant disease of the hematopoietic system caused by heterozygous mutations in RUNX1 (OMIM#601399). FPDMM is characterized by thrombocytopenia, abnormal platelet function and an increased risk of developing other blood disorders or cancers such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (Sakurai et al., 2016) . iPSCs lines from this pathology have been previously obtained (Sakurai et al., 2014) . In this study, we report the generation of a new cellular line from peripheral blood mononuclear cells (PBMCs) obtained from a FPDMM patient carrying a non-previously reported variant (p.Thr196Ala) in the RUNX1 locus, which was identified by our next-generation sequencing panel (Bastida et al., 2018) .
CytoTune iPS 2.0 Sendai Reprogramming kit (ThermoFisher Scientific) was used to reprogram PBMCs from the FDPMM patient. PBMCs were transduced with Sendai virus (SeV) vectors expressing and delivering the reprogramming factors OCT3/4, SOX2, KLF4 and c-MYC. 2-3 weeks after viral exposure several clones were selected and characterized as described below.
Firstly, the presence of the variant p.Thr196Ala in the exon 6 of the RUNX1 locus in the GENYOi005-A cell line was confirmed by Sanger sequencing. As shown in Fig. 1A , PBMCs from the patient (FPD-PBMCs) and GENYOi005-A cells share the same heterozygous variant. Short Tandem Repeat polymorphism (STR) analysis confirmed the same genetic identity between both samples. GENYOi005-A silenced the expression of exogenous reprogramming transgenes ( Fig. 1B) and activated the expression of the endogenous pluripotent transcription factors (SOX2, REX1, NANOG and OCT4) ( Fig. 1C ). Importantly, GENYOi005-A cells showed normal karyotype (46, XX) ( Fig. 1D ) and alkaline phosphatase activity (Fig. 1E ). In addition, expression of the pluripotent markers SSEA3, SSEA4, Tra1-60, Tra1-81 and Oct3/4 was confirmed by flow cytometry analysis ( Fig. 1F ). Moreover, mycoplasma analysis was negative for GENYOi005-A cell line.
Finally, to demonstrate the capacity of GENYOi005-A to differentiate into the three germ layers in vitro and in vivo, embryoid bodies (EBs) formation assays ( Fig. 1G ) and teratoma formation assays were accomplished ( Fig. 1H ). EBs and teratomas derived from this cell line showed specific structures from endoderm (ciliated epithelium), mesoderm (cartilage) and ectoderm (neural rosettes). Besides, we also detected the expression of representative markers of the three germ layers: ectoderm (β3-Tubulin), mesoderm (Vimentin) and endoderm (Cytokeratin CKAE1-AE) ( Table 1) .
Materials and methods

Reprogramming of GENYOi005-A line
The peripheral blood sample was obtained from a woman with FPDMM after informed consent according to the Local Ethical Committee of the Instituto de Investigación Biomédica (IBSAL, Salamanca, Spain), the Andalusian Ethics Review Board for Cellular Reprogramming requirements and with Spanish and EU legislation. PBMCs from the patient were isolated by centrifugation using Ficoll Paque™ PLUS (GE Healthcare) and cultured for four days in StemSpan™ SFEM (StemCell Technologies) supplemented with hSCF, hFLT3L, hIL6 and hIL3 (Peprotech). Then, 3 million PBMCs were transduced with Sendai virus (SeV) using CytoTune®-iPS 2.0 Reprogramming kit (Life Technologies, Invitrogen) and plated over 12-well fibronectin-coated plate (BD BioCoat™) as formerly described (Lopez-Onieva et al., 2016) . Four weeks after reprogramming, GENYOi005-A cells were accommodated to grow in Essential 8 medium (E8) on Matrigel (BD Bioscience). GENYOi005-A cells were split weekly at a ratio of 1:8 using PBS/EDTA (0.5 mM) and cultured at 37°C, 5% CO 2 .
Mutational analysis
Genomic DNA was isolated from PBMCs of the FPDMM patient, GENYOi005-A line and a healthy control iPSC line (PBMC1-iPS4F1) using the DNA extraction kit (Qiagen). PCR amplification was performed in all samples using a set of primers that recognizes RUNX1 exon 6 (Set RUNX1, Table 2 ) following the manufacturer's instructions in a SureCycler 8800 thermal cycler (Agilent). Amplified fragments were run and sequenced using RUNX1 Forward primer, in an ABI 3130 genetic analyzer (Applied Biosystems, Life Technologies).
Short Tandem Repeat polymorphism (STR) profiling
The genetic signature of FPDMM-PBMCs and GENYOi005-A cell line was determined as previously described (Lopez-Onieva et al., 2016) . This information is available with the authors.
RT-PCR analysis
Total RNA from GENYOi005-A cell line, the control PBMC1-iPS4F1line and PBMCs from FPDMM patient was isolated with the High pure RNA isolation kit (Roche) and cDNA was produced with the Transcription First Strand c-DNA synthesis kit (Roche) according to the manufacturer's instructions. PCR was performed using GoTaq Flexi DNA Polimerase kit (Promega) in a SureCycler 8800 thermal cycler (Agilent). PCR fragments were visualized in an agarose gel. SeV, KLF4, c-MYC and KOS primer sets were used to analyse the presence of exogenous genes and Oct3/4, SOX2, NANOG, REX1 and β-ACTIN primer sets used to verify the expression of pluripotency markers as previously described (Montes et al., 2019) . FPDMM-PBMCs transduced cells at day 4 subsequent to SeV exposure was used as a positive control and PBMC1-iPS4F1line as a negative control for exogenous reprogramming factors. For endogenous pluripotent transcription factors, PBMC1-iPS4F1 iPSC line was used as a positive control and FPDMM-PBMCs as a negative control. Primer sequences used are shown in Table 2 .
Karyotyping
Chromosomal analysis of GENYOi005-A line at passage 13 was accomplished by GTG-banding analysis at the Andalusian Public Health System Biobank (Spain). 20 metaphases were evaluated following the International System Cytogenetics Nomenclature recommendations.
Alkaline phosphatase
After five days in culture on a 24-well plate (Corning), GENYOi005-A colonies were assayed for phosphatase alkaline enzymatic activity using Alkaline Phosphatase detection kit (Merck-Millipore) following manufacturer's instructions.
Flow cytometry analysis
GENYOi005-A cell line colonies were dissociated with Tryple Express (Life Technologies) and cell suspension was stained with SSEA3 (PE, BioScience), SSEA4 (Alexa Fluor® 647, BD Pharmingen), Tra1-60 (PE, BioScience) and Tra1-81 (Alexa Fluor® 647, BD Pharmingen) antibodies for 20 min. Intracellular staining for Oct3/4 was performed by Histological sections from 10-week teratomas developed in the dorsal flanks of NOD/LtSz-scid interleukin-2Rγ-/-mice after injecting 2 million GENYOi005-A cells. Hematoxylin and eosin (H&E) staining allowed us to identify several morphological structures characteristics for each germ layer: Ciliated Epithelium (Endoderm), Cartilage (Mesoderm) and Neural Rosette (Ectoderm). In the right panels, immunohistochemistry analysis confirmed differentiation to endoderm (CK-AE1-AE3), mesoderm (Vimentin) and ectoderm (GFAP). (Scales bar from 50-250 µm). several incubations of 15 min using fixation and permeabilization solutions (A and B Fix and Perm Solutions (BD BioScience)). Then, GENYOi005-A cells were incubated with Oct3/4 (BD BioScience) primary antibody, and subsequently with FITC-conjugated secondary antibody (BD BioScience). An isotype-match antibody was used as a negative control. Viable cells were identified with 7-aminoactinomycin D staining and were analyzed in the BD FACSVerse™ flow cytometer (BD Bioscience) using BD FACSuite™ software (BD Bioscience) for acquisition and FlowJo™ for analysis (FlowJo, LLC-BD Bioscience).
Embryo body (EB) differentiation assay
GENYOi005-A colonies were gently scraped off the flask after treatment with collagenase IV (Invitrogen), re-suspended into Essential 6 medium (E6) after centrifugation, transferred into low attachment 6well plates (Corning) and cultured in an incubator at 37°C, 5% CO 2 . After 16 days, EBs were collected, fixed, embedded in paraffin and sectioned for histological and immunocytochemistry analysis. Sectioned EBs were stained with hematoxylin and eosin (H&E) for histological analysis. Immunocytochemistry analysis was performed in the Pathology Department of the University Hospitals of Granada. Briefly, antigen retrieval was done by boiling sections for 20 min at 95°C in citrate buffer (pH = 6) in a PT-Module (ThermoScientific). The Master Polymer Plus Detection System (Peroxidase) (Master Diagnostica) was used as a visualization system following manufacturer's instructions, in an Autostainer 480 S-2D automatic immunostainer (ThermoScientific). Diaminobenzidine (DAB) was used as the chromogen. Primary antibodies for β-III-Tubulin (ectoderm), Vimentin (mesoderm) and CKAE1-EA3 (endoderm) are included in Table 2 .
In vivo teratoma formation
GENYOi005-A cells were dissociated with collagenase IV (Invitrogen) and resuspended in PBS with 30% Matrigel. 2 million cells were subcutaneously injected into the dorsal flanks of NOD/LtSz-scid interleukin-2Rγ _/_ mice (The Jackson Laboratory). At week 10 postimplantation, teratomas were collected, fixed in formaldehyde, embedded in paraffin, sectioned and stained with H&E for histological analysis. Immunocytochemistry analysis for CKAE1-AE3 (endoderm), Vimentin (mesoderm) and β-III-Tubulin (ectoderm) was performed on sectioned slides as described above.
Mycoplasma analysis
Mycoplasma test for GENYOi005-A cell line was performed by quantitative PCR analysis (Venor GeM-qEP, Minerva Biolabs) at the Genomics and Genotyping Unit in GENyO, Spain.
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